Cadonilimab+ Paclitaxel (Albumin-bound) Treat Advanced Gastric Adenocarcinoma With PD-(L)1 Inhibitors Resistance
Cadonilimab combined with paclitaxel (albumin-bound) treat advanced gastric adenocarcinoma or esophagogastric junction adenocarcinoma with PD-(L)1 inhibitors resistance
Gastric Adenocarcinoma
DRUG: cadonilimab combined +paclitaxel (albumin-bound)
6-month progression-free survival assessed by RECIST v1.1, 6-month progression-free survival assessed by RECIST v1.1, 6-month
Objective response rate (ORR), Objective response rate (ORR), Until the investigator determines that there is no longer a clinical benefit ， toxicity is intolerable, treatment is completed at 24 months, or other protocol criteria for disco|disease control rate (DCR), disease control rate (DCR), Until the investigator determines that there is no longer a clinical benefit ， toxicity is intolerable, treatment is completed at 24 months, or other protocol criteria for disco|duration of response (DoR), duration of response (DoR), Until the investigator determines that there is no longer a clinical benefit ， toxicity is intolerable, treatment is completed at 24 months, or other protocol criteria for disco|progression-free survival (PFS), progression-free survival (PFS), Until the investigator determines that there is no longer a clinical benefit ， toxicity is intolerable, treatment is completed at 24 months, or other protocol criteria for disco|overall survival (OS), overall survival (OS), Until the investigator determines that there is no longer a clinical benefit ， toxicity is intolerable, treatment is completed at 24 months, or other protocol criteria for disco|Incidence and severity of adverse events (AES), Incidence and severity of adverse events (AES) with clinically significant unusual, Until the investigator determines that there is no longer a clinical benefit ， toxicity is intolerable, treatment is completed at 24 months, or other protocol criteria for disco
PD-L1 expression, PD-L1 expression, Until the investigator determines that there is no longer a clinical benefit ， toxicity is intolerable, treatment is completed at 24 months, or other protocol criteria for disco|MMR status, MMR status, Until the investigator determines that there is no longer a clinical benefit ， toxicity is intolerable, treatment is completed at 24 months, or other protocol criteria for disco
An open, multicenter, Phase II study of cadonilimab combined with paclitaxel (albumin-bound) in the treatment of advanced gastric adenocarcinoma or esophagogastric junction adenocarcinoma that has failed prior treatment with PD-(L)1 inhibitors